Andelyn Biosciences, Inc., a Contract Development and Manufacturing Organization (CDMO) specializing in cell and gene therapy, has joined forces with The Ohio State University Gene Therapy Institute to collaborate on the development and clinical production of innovative gene therapies.
This partnership aims to streamline the process of bringing Ohio State's experimental gene therapies for various neurological disorders, such as Parkinson's, amyotrophic lateral sclerosis (ALS), and Huntington's, from conceptualization to manufacturing for clinical trials. Researchers at Ohio State will benefit from Andelyn's expertise in adherent and suspension platforms, extensive viral vector development, process optimization, and full-scale manufacturing capabilities. By working together, Ohio State and Andelyn aim to enhance program efficiency and expedite the path to clinical trials.
The joint efforts in developing cutting-edge gene therapies further solidify the established collaboration between Ohio State and Andelyn, providing newfound hope for patients suffering from genetically linked neurological diseases. The robust partnership between both entities ensures that Ohio State's gene therapies reach patients with the utmost speed and quality.
With Andelyn's Good Manufacturing Practice (GMP) manufacturing capabilities now fully operational at the state-of-the-art 180,000 sq. ft. Andelyn Corporate Center (ACC), Andelyn takes pride in offering its clients top-tier quality and large-scale suspension clinical and commercial manufacturing in the thriving biotech hub of Columbus, Ohio. The ACC complements Andelyn's two other Columbus facilities, which focus on pre-clinical process development and plasmid manufacturing.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!